Evidence map›Paper›PMID 35963986›Full record

Trial reportInternational journal of hematology2022

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.

Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu and 2 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. An Overview of Advances in Rare Cancer Diagnosis and Treatment.International journal of molecular sciences · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Takaaki OnoHamamatsu University Hospital, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan. takaono@hama-med.ac.jp.ORCID http://orcid.org/0000-0003-3922-7432
Masayuki HinoOsaka City University Hospital, Osaka, Japan.
Itaru MatsumuraKindai University Hospital, Osaka, Japan.
Shin FujisawaYokohama City University Medical Center, Yokohama, Japan.
Kenichi IshizawaYamagata University Hospital, Yamagata, Japan.
Emiko SakaidaChiba University Hospital, Chiba, Japan.
Naohiro SekiguchiNational Hospital Organization Disaster Medical Center, Tokyo, Japan.
Chiho OnoPfizer Japan Inc, Tokyo, Japan.
Mana AizawaPfizer R and D Japan G.K, Tokyo, Japan.
Yusuke TanetsuguPfizer R and D Japan G.K, Tokyo, Japan.
Yuichiro KoidePfizer R and D Japan G.K, Tokyo, Japan.
Naoto TakahashiAkita University Hospital, Akita, Japan.
Pfizer (Japan) · JPAkita University Hospital · JPChiba University Hospital · JPHamamatsu University · JPKindai University Hospital · JPNational Hospital Organization · JPOsaka City University Hospital · JPYamagata University Hospital · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dose of 400 mg once daily in Japanese patients (n = 60) with newly diagnosed CP-CML. The minimum follow-up period was 3 years and median duration of treatment was 35.9 months. At study completion, 60% of patients were still on treatment. Cumulative rates of major molecular response (MMR), molecular response

Indexed as

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseAniline CompoundsFollow-Up StudiesHumansImatinib MesylateJapanNitrilesQuinolinesAniline CompoundsAntineoplastic AgentsbosutinibImatinib MesylateNitrilesQuinolinesBosutinibChronic myeloid leukemiaJapanTyrosine kinase inhibitor

Identifiers

PMID35963986
PMCPMC9668794
OpenAlexW4291247436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.